Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

查看其它語言版本

新聞

2011年2月14日澳洲股市:Black Fire Minerals (ASX:BFE)將收購美國鎢/銅項目

🕔2/14/2011 12:20:00 PM 13341

2011年2月14日澳洲股市報告包括:Black Fire Minerals (ASX:BFE)將收購美國內華達州已開發的Pilot Mountain鎢-銅項目的100%股份;Virax Holdings Limited (ASX:VHL)將開發一種皮膚癌新藥;Southern Cross Goldfields Limited (ASX:SXG)在西澳發現近地表高品位金礦;Prosperity Resources Limited (ASX:PSP)在印尼開始鑽探。

閱讀全文
###

137,644 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 21) (過去30日: 100) (自發布以來: 11542) 

公司詳細

    傳真
  • (03) 9853 5134 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.virax.com.au/

更多新聞紀錄

  • 2025/03/31: Prescient Therapeutics - Investor Briefing*
  • 2025/03/26: PTX Opens First Clinical site for PTX-100 Phase 2a Study*
  • 2025/03/24: Change of Chief Medical Officer*
  • 2025/03/21: PTX-100 clinical data presented at leading TCL meeting*
  • 2025/03/17: Change of Director's Interest Notice*
  • 2025/03/11: Change of Board Chair*
  • 2025/02/21: Appendix 4D and Half Year Financial Report*
  • 2025/01/31: December 2024 Quarterly Update and Appendix 4C - amended*
  • 2025/01/31: December 2024 Quarterly Update and Appendix 4C*
  • 2025/01/23: OmniCAR technical issues resolved and program to progress*
*refer to company website